Latanoprost/timolol

Latanoprost/timolol
Combination of
Latanoprost	Prostaglandin
Timolol	Beta blocker
Clinical data
Trade names	Xalacom
Routes of; administration	Eye drops
ATC code	S01ED51 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only);
Identifiers
PubChem CID	56841581;
KEGG	D07505;
CompTox Dashboard (EPA)	DTXSID401005716 ;

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Latanoprost/timolol, sold under the brand name Xalacom, is a combination drug used for the treatment of glaucoma, consisting of latanoprost (increase uveoscleral outflow of aqueous humor^[3]) and timolol (a beta blocker decreasing the production of aqueous fluid).

Society and culture

Brand names

In some countries, Xalacom is marketed by Viatris after Upjohn was spun off from Pfizer.^[4]^[5]

References

^ "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 30 March 2024.
^ "Summary of Product Characteristics (SmPC)". (emc). 13 June 2022. Retrieved 31 March 2024.
^ Patel SS, Spencer CM (1996). "Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension". Drugs Aging. 9 (5): 363–378. doi:10.2165/00002512-199609050-00007. PMID 8922563. S2CID 25169085.
^ "Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan". Pfizer. 16 November 2020. Retrieved 17 June 2024 – via Business Wire.
^ "Brands". Viatris. 16 November 2020. Retrieved 17 June 2024.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[1] "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 30 March 2024.

[2] "Summary of Product Characteristics (SmPC)". (emc). 13 June 2022. Retrieved 31 March 2024.

[3] Patel SS, Spencer CM (1996). "Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension". Drugs Aging. 9 (5): 363–378. doi:10.2165/00002512-199609050-00007. PMID 8922563. S2CID 25169085.

[4] "Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan". Pfizer. 16 November 2020. Retrieved 17 June 2024 – via Business Wire.

[5] "Brands". Viatris. 16 November 2020. Retrieved 17 June 2024.

[1]